See more : DTE Energy Company 2021 Series (DTG) Income Statement Analysis – Financial Results
Complete financial analysis of MedMen Enterprises Inc. (MMNFF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MedMen Enterprises Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Clearfield, Inc. (CLFD) Income Statement Analysis – Financial Results
- NamSys Inc. (NMYSF) Income Statement Analysis – Financial Results
- Hunan Nanling Industrial Explosive Materials Co., Ltd. (002096.SZ) Income Statement Analysis – Financial Results
- FirstService Corporation (FSV) Income Statement Analysis – Financial Results
- Radium Life Tech. Co., Ltd. (2547.TW) Income Statement Analysis – Financial Results
MedMen Enterprises Inc. (MMNFF)
About MedMen Enterprises Inc.
MedMen Enterprises Inc., together with its subsidiaries, operates as a cannabis company in the United States. The company cultivates, produces, distributes, and retails recreational and medicinal cannabis under the MedMen Red and LuxLyte brand names. As of December 25, 2021, it operated 29 stores in California, Florida, Nevada, Illinois, Arizona, Massachusetts, and New York. MedMen Enterprises Inc. is headquartered in Culver City, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 140.81M | 145.07M | 157.11M | 129.96M | 39.78M | 2.67M | 20.07K | 26.65K | 20.64K | 24.92K | 19.66K | 27.66K | 18.14K | 33.60K | 36.42K | 22.18K | 20.28K | 19.34K | 30.11K | 0.00 | 305.46K |
| Cost of Revenue | 71.08M | 77.78M | 98.99M | 69.09M | 25.93M | 1.80M | 7.89K | 7.66K | 7.96K | 7.78K | 9.02K | 10.70K | 9.33K | 10.32K | 9.36K | 10.82K | 8.19K | 7.78K | 19.30K | 0.00 | 395.02K |
| Gross Profit | 69.73M | 67.29M | 58.12M | 60.88M | 13.85M | 868.14K | 12.18K | 19.00K | 12.69K | 17.14K | 10.63K | 16.96K | 8.81K | 23.28K | 27.06K | 11.36K | 12.08K | 11.56K | 10.81K | 0.00 | -89.56K |
| Gross Profit Ratio | 49.52% | 46.39% | 36.99% | 46.84% | 34.81% | 32.49% | 60.69% | 71.27% | 61.46% | 68.78% | 54.09% | 61.32% | 48.56% | 69.30% | 74.31% | 51.23% | 59.59% | 59.76% | 35.90% | 0.00% | -29.32% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 108.72M | 124.59M | 200.27M | 234.65M | 98.18M | 14.14M | 136.18K | 240.61K | 133.04K | 236.99K | 53.70K | 28.22K | 41.69K | 41.73K | 11.11K | 8.91K | 9.37K | 19.11K | 45.59K | 0.00 | 0.00 |
| Selling & Marketing | 3.21M | 1.11M | 10.64M | 27.55M | 7.01M | 323.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 111.93M | 125.70M | 210.92M | 262.20M | 105.20M | 14.46M | 136.18K | 240.61K | 133.04K | 236.99K | 53.70K | 28.22K | 41.69K | 41.73K | 11.11K | 8.91K | 9.37K | 19.11K | 45.59K | 74.82K | 171.76K |
| Other Expenses | 19.10M | 30.89M | 39.95M | 20.98M | 5.26M | 1.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 216.33K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 131.03M | 156.59M | 250.87M | 283.17M | 110.45M | 15.66M | 136.18K | 240.61K | 133.04K | 236.99K | 53.70K | 28.22K | 41.69K | 41.73K | 11.11K | 8.91K | 9.37K | 19.11K | 45.59K | 74.82K | 179.99K |
| Cost & Expenses | 202.11M | 234.37M | 349.86M | 352.26M | 136.39M | 17.46M | 144.07K | 248.26K | 140.99K | 244.77K | 62.73K | 38.92K | 51.02K | 52.05K | 20.47K | 19.73K | 17.56K | 26.90K | 64.89K | 74.82K | 575.01K |
| Interest Income | 91.59K | 649.23K | 766.04K | 701.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 43.07M | 61.37M | 49.49M | 22.82M | 16.11M | 512.44K | 135.37 | 6.53K | 2.46K | 30.07K | 35.41K | 34.97K | 35.93K | 30.44K | 37.00K | 31.38K | 29.77K | 17.16K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 25.74M | 34.46M | 43.71M | 23.54M | 5.15M | 1.57M | 22.82K | 6.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 216.33K | 0.00 | 10.08K | 0.00 | 0.00 |
| EBITDA | -35.56M | -54.84M | -149.04M | -198.75M | -91.45M | -13.22M | -124.01K | -221.61K | -120.35K | -219.85K | -43.07K | -11.26K | -32.88K | -18.45K | 15.95K | 2.45K | 219.04K | -7.55K | -24.71K | -74.82K | -269.55K |
| EBITDA Ratio | -25.26% | -37.81% | -94.86% | -152.93% | -229.87% | -494.85% | -618.00% | -831.49% | -582.98% | -882.08% | -219.12% | -40.73% | -181.26% | -54.90% | 43.80% | 11.04% | 1,080.18% | -39.05% | -82.07% | 0.00% | -88.24% |
| Operating Income | -61.30M | -89.30M | -192.75M | -222.30M | -96.60M | -14.79M | -124.01K | -228.14K | -120.35K | -219.85K | -43.07K | -11.26K | -32.88K | -18.45K | 15.95K | 2.45K | 2.72K | -7.55K | -34.79K | -74.82K | -269.55K |
| Operating Income Ratio | -43.53% | -61.56% | -122.68% | -171.05% | -242.83% | -553.54% | -618.00% | -855.98% | -582.98% | -882.08% | -219.12% | -40.73% | -181.26% | -54.90% | 43.80% | 11.04% | 13.40% | -39.05% | -115.55% | 0.00% | -88.24% |
| Total Other Income/Expenses | -114.15M | -67.40M | -328.92M | -22.30M | -11.01M | -2.91M | -18.81 | 0.00 | -2.46K | -30.07K | -35.41K | -34.97K | -35.93K | -30.44K | -37.00K | -31.38K | 186.55K | -17.16K | 360.22K | 0.00 | -1.00M |
| Income Before Tax | -175.45M | -143.61M | -515.35M | -263.23M | -110.73M | -15.38M | -124.14K | -228.14K | -122.80K | -249.92K | -78.48K | -46.23K | -68.81K | -48.88K | -21.05K | -28.93K | 189.27K | -24.72K | 325.43K | 0.00 | -1.27M |
| Income Before Tax Ratio | -124.60% | -99.00% | -328.01% | -202.54% | -278.32% | -575.46% | -618.67% | -855.98% | -594.87% | -1,002.74% | -399.26% | -167.16% | -379.31% | -145.49% | -57.81% | -130.46% | 933.37% | -127.80% | 1,080.98% | 0.00% | -416.30% |
| Income Tax Expense | -9.90M | 1.83M | -39.60M | 13.81M | 1.54M | 43.17K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.77K | 0.00 | 0.00 | 75.18K | 0.00 |
| Net Income | -165.55M | -145.45M | -475.75M | -277.05M | -112.26M | -15.42M | -124.14K | -228.14K | -122.80K | -249.92K | -78.48K | -46.23K | -68.81K | -48.88K | -21.05K | -28.93K | 189.27K | -24.72K | 325.43K | -75.18K | -1.27M |
| Net Income Ratio | -117.57% | -100.26% | -302.81% | -213.17% | -282.19% | -577.07% | -618.67% | -855.98% | -594.87% | -1,002.74% | -399.26% | -167.16% | -379.31% | -145.49% | -57.81% | -130.46% | 933.37% | -127.80% | 1,080.98% | 0.00% | -416.30% |
| EPS | -0.14 | -0.27 | -1.76 | -2.62 | -2.77 | -26.33 | -0.21 | -0.56 | -0.50 | -0.93 | -1.76 | -1.03 | -1.54 | -1.09 | -0.47 | -0.65 | 4.24 | -0.55 | 7.28 | -1.68 | -28.73 |
| EPS Diluted | -0.14 | -0.27 | -1.76 | -2.62 | -2.77 | -26.33 | -0.21 | -0.56 | -0.50 | -0.93 | -1.76 | -1.03 | -1.54 | -1.09 | -0.47 | -0.65 | 4.24 | -0.55 | 7.28 | -1.68 | -28.73 |
| Weighted Avg Shares Out | 1.15B | 530.98M | 270.42M | 105.92M | 40.48M | 585.58K | 585.58K | 410.57K | 245.24K | 268.30K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.26K |
| Weighted Avg Shares Out (Dil) | 1.15B | 530.98M | 270.42M | 105.92M | 40.48M | 585.58K | 585.58K | 410.57K | 245.24K | 268.30K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.26K |
Where Is The Value In Cannabis Stocks?
Bengal Capital's Jerry Derevyanny moved away from top multi-state operators (MSOs) to find the most value. Why EBITDA falls short as a useful metric to measure cannabis stocks.
Cannabis exec Adam Bierman wins MedMen arbitration settlement and eyes pot biz again
Adam Bierman made a name for himself as a co-founder of MedMen in 2010 by modeling cannabis dispensaries after the Apple Store and later announcing what would have been the largest merger in the cannabis industry at the time.
Cannabis Consolidation Continues
A prolonged downturn and liquidity crunch have led to more consolidation across the sector. Some are strong, some are surviving.
What's The Deal With New York Cannabis?
Legal cannabis has officially hit New York. Two long-time NY advocates, Allan Gandelman and Kaelan Castetter, provide context for this moment.
Why Cannabis REITs Could Get a Whole Lot Riskier
A legal battle involving a top multi-state operator could create a dangerous precedent for the cannabis industry.
3 Marijuana Stocks For Your Investment Portfolio
Are You Buying Marijuana Stocks? Here Is The Potential Upside The post 3 Marijuana Stocks For Your Investment Portfolio appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.
Cannabis stocks cool off after previous day's rally as optimism around rescheduling fades
Speculation over potential rescheduling of cannabis and federal legalization cooled off considerably Friday, sending pot stocks into the red after spiking in the previous session.
3 Marijuana Stocks To Buy In The Stocks Market Right Now
Marijuana Stocks To Watch At The End Of The Month The post 3 Marijuana Stocks To Buy In The Stocks Market Right Now appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.
MedMen puts New York business on selling block after Ascend scraps deal
Los Angeles-based cannabis company MedMen Enterprises Inc. MMNFF, -1.38% MMEN, -6.67% said late Monday it's currently exploring strategic alternatives for its New York business. The company owns a cultivation facility in New York and four dispensaries under the state's existing...
California Cannabis Market - Deep Dive, Part II (Podcast Transcript)
Emily Paxhia and Hirsh Jain catch us up on the California cannabis market and beyond. Elimination of cultivation tax, but other taxes remain.
Source: https://incomestatements.info
Category: Stock Reports